| Cervical cancer |
| Malea |
0.411 |
0.411 |
0.411 |
| Female |
0.76 |
0.76 |
0.76 |
| Protection against cervical HPV infections becoming persistent |
0.988 |
0.988 |
0.988 |
| Protection against HPV-related CIN |
0.97 |
0.97 |
0.97 |
| Vaginal and vulvar cancers |
| Malea |
0.411 |
0.621 |
0.621 |
| Female |
0.76 |
0.963 |
0.963 |
| Protection against vaginal/vulvar HPV infections becoming persistent |
0.988 |
0.984 |
0.984 |
| Protection against HPV-related /VaIN/VIN |
1 |
1 |
1 |
| Anal cancers |
| Male |
0.762 |
1 |
0.762 |
| Female |
0.762 |
1 |
0.762 |
| Protection against anal HPV infections becoming persistent |
|
|
|
| Male |
0.938 |
0.999 |
0.938 |
| Female |
0.938 |
0.999 |
0.938 |
| Protection against HPV-related AIN |
0.655 |
1 |
0.655 |
| H&N cancers |
| Male |
0.411 |
0.621 |
0.621 |
| Female |
0.760 |
0.963 |
0.963 |
| Protection against H&N infections becoming persistent |
|
|
|
| Male |
0.787 |
0.96 |
0.96 |
| Female |
0.988 |
0.984 |
0.984 |
| Protection against HPV-related H&N neoplasia |
0 |
0 |
0 |
| Penile cancer |
| Male |
0.411 |
0.621 |
0.621 |
| Femaleb |
0.760 |
0.963 |
0.963 |
| Protection against penile HPV-16/18 infections becoming persistent |
|
|
|
| Protection against HPV-related PIN |
0.787 |
0.960 |
0.960 |
| Vaccine efficacy against HPV-6/11 infection |
HPV-6 |
HPV-11 |
|
| Females |
0.761 |
0.761 |
|
| Males |
0.49 |
0.57 |
|
| Protection against HPV-6/11–related genital warts |
|
|
|
| Females |
0.989 |
1 |
|
| Males |
0.843 |
0.909 |
|
| Protection against HPV-6/11–related CIN1 |
1 |
1 |
|